Zoetis' (ZTS) Simparica Should Gain Approval in March - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
February 16, 2016 7:02 AM ESTZoetis (NYSE: ZTS) reported Q4 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.25 billion.
GUIDANCE:
Zoetis sees FY2016 EPS of $1.71-$1.81, versus the consensus of $1.81. Zoetis sees FY2016 revenue of $4.65-4.775 billion, versus the consensus of $4.82 billion.
In 2015, Zoetis continued to affirm our reputation as the global leader in the animal health industry with a strong financial performance, ongoing investments in... More
